聚乙二醇干扰素α-2a对慢性乙型肝炎患者外周血单个核细胞Galectin-3表达的影响  

Galectin-3 expression in peripheral blood mononuclear cells of chronic hepatitis B patients treated with pegylated interferon alpha-2a

作　　者：李宜[1] 余龙[2] 吴晓玲[1] 

机构地区：[1]安徽省立医院感染科,合肥230001 [2]安徽省六安市人民医院感染科

出　　处：《中华肝脏病杂志》2014年第5期336-339,共4页Chinese Journal of Hepatology

摘　　要：目的研究聚乙二醇干扰素α-2a（Peg—IFNα-2a）治疗慢性乙型肝炎（CHB）患者的应答情况与外周血单个核细胞（PBMC）Galectin-3表达的关系，探讨Galectin-3对Peg-IFN α-Za抗病毒疗效的影响。方法治疗组CHB患者接受Pe扩IFN α-2a治疗48周，随访24周，根据血清学以及病毒学检测结果，分为治疗24周有效组、治疗48周有效组及治疗无效组。PCR和Westernblot方法检测治疗前、治疗24周时及治疗48周时患者PBMCGalectin-3基因和蛋白质表达情况。根据数据类型分别采用t检验或χ^2检验进行数据比较。结果Peg-IFN α-2a治疗有效组患者PBMC Galectin-3的基因及蛋白质相对表达量明显高于正常对照组和治疗无效组（P值均〈0．05）；治疗24周有效组Galectin-3的基因及蛋白质相对表达量在24周和48周时均明显高于正常对照组（P值均〈0．05）。治疗48周有效组在48周时的Galectin-3基因和蛋白质相对表达量明显高于治疗24周时（P〈0．05）。结论Peg-IFN α-2a可能通过上调人体外周血单核细胞Galectin-3表达发挥抗病毒作用。Objective To study the relationship between therapeutic efficacy of pegylated interferon alpha-2a （Peg-IFNct-2a） in patients with chronic hepatitis B （CHB） and expression of Galecfin-3 in peripheral blood mononuclear cells （PBMCs）. Methods Fifty CHB patients treated with a 48-week course of Peg-IFNα-2a （180 μg/week, subcutaneous） were divided into groups according to treatment response, with 14 patients in the 24-week responder group, 21 patients in the 48-week responder group and 15 patients in the non-responder groups. Twenty healthy vounteers served as the normal control group. Gene and protein expression of Galectin-3 in PBMCs was detected by PCR and western blotting. Results PBMC expression of Galectin-3 was significantly higher in the effective treatment （responders） group compared to the control group and the non-responder group. In addition, the 24-week responders had significantly higher than the 48-week responders, and the 48-week responders had significantly higher Galectin-3 expression than the non-responders at 24 weeks. Conclusion Peg-IFNα-2a may inhibit HBV DNA replication by up-regulating the expression of Galectin-3 in PBMCs.

关 键 词：肝炎 乙型 慢性 干扰素Α-2A 外周血单个核细胞 GALECTIN 

分 类 号：R512.62[医药卫生—内科学]